Isthmus Partners LLC Has $1.57 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Isthmus Partners LLC boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.0% during the 2nd quarter, reports. The institutional investor owned 50,981 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,000 shares during the period. Isthmus Partners LLC’s holdings in Supernus Pharmaceuticals were worth $1,570,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Eagle Bay Advisors LLC acquired a new position in Supernus Pharmaceuticals during the second quarter worth $39,000. First Horizon Advisors Inc. raised its holdings in shares of Supernus Pharmaceuticals by 105.7% in the first quarter. First Horizon Advisors Inc. now owns 1,333 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 685 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at about $45,000. Lazard Asset Management LLC purchased a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at about $50,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at about $213,000.

NASDAQ SUPN traded up $0.41 during trading hours on Wednesday, reaching $27.34. 626 shares of the company were exchanged, compared to its average volume of 502,525. Supernus Pharmaceuticals, Inc. has a 1 year low of $17.20 and a 1 year high of $34.29. The business’s 50 day simple moving average is $26.55 and its 200-day simple moving average is $28.41. The company has a quick ratio of 2.05, a current ratio of 2.26 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $1.45 billion, a P/E ratio of 14.56 and a beta of 1.22.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Wednesday, August 4th. The specialty pharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.26. Supernus Pharmaceuticals had a net margin of 17.55% and a return on equity of 13.39%. The business had revenue of $141.33 million during the quarter, compared to the consensus estimate of $135.50 million. During the same quarter last year, the company posted $0.65 earnings per share. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.02 earnings per share for the current year.

Separately, Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 10th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Read More: What are the advantages to having securities held in street name?

Want to see what other hedge funds are holding SUPN? Visit to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with's FREE daily email newsletter.